Literature DB >> 17308794

Schistosoma mansoni antigen-driven interleukin-10 production in infected asthmatic individuals.

Luciana S Cardoso1, Sergio C Oliveira, Lucila G G Pacífico, Alfredo M Góes, Ricardo R Oliveira, Cristina T Fonseca, Edgar M de Carvalho, Maria Ilma Araújo.   

Abstract

UNLABELLED: Asthmatics infected with Schistosoma mansoni have a less severe course of asthma and an inhibition of the Th2 inflammatory response that seems to be mediated by interleukin (IL-10). The objective of this study was to evaluate the capacity of some S. mansoni antigens to stimulate IL-10 production in vitro by cells of asthmatic infected individuals. Peripheral bloods mononuclear cells were stimulated with the S. mansoni recombinant antigens Sm22.6, Sm14, P24, and PIII antigen. IL-10 was measured in the supernatants of cultures. As the recombinant antigens were cloned in Escherichia coli, we blocked contaminant endotoxin with polymyxin B added to the cultures. We demonstrated that all antigens used drove high production of IL-10 in S. mansoni infected individuals (n = 13, 408 +/- 514 and 401 +/- 383 pg/ml, 484 +/- 245 pg/ml, 579 +/- 468 pg/ml, respectively). In asthmatics infected with S. mansoni (n = 21) rP24 induced higher levels of IL-10 (565 +/- 377 pg/ml) when compared to PIII, rSm14 and rSm22.6 (184 +/- 209 pg/ml; 292 +/- 243 pg/ml; 156 +/- 247 pg/ml, respectively).
CONCLUSION: the S. mansoni antigens evaluated in this study stimulated IL-10 production by cells from infected individuals and therefore they have the potential to be used as a modulator of the inflammatory response in asthma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17308794     DOI: 10.1590/s0074-02762006000900055

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  7 in total

Review 1.  A double edged sword: Schistosoma mansoni Sm29 regulates both Th1 and Th2 responses in inflammatory mucosal diseases.

Authors:  Sergio C Oliveira; Barbara C Figueiredo; Luciana S Cardoso; Edgar M Carvalho
Journal:  Mucosal Immunol       Date:  2016-08-24       Impact factor: 7.313

2.  Schistosoma mansoni antigens modulate the allergic response in a murine model of ovalbumin-induced airway inflammation.

Authors:  L S Cardoso; S C Oliveira; A M Góes; R R Oliveira; L G Pacífico; F V Marinho; C T Fonseca; F C Cardoso; E M Carvalho; M I Araujo
Journal:  Clin Exp Immunol       Date:  2010-02-02       Impact factor: 4.330

Review 3.  Mycobacterium-Induced Th1, Helminths-Induced Th2 Cells and the Potential Vaccine Candidates for Allergic Asthma: Imitation of Natural Infection.

Authors:  Mohamed Hamed Abdelaziz; Xiaoyun Ji; Jie Wan; Fatma A Abouelnazar; Sayed F Abdelwahab; Huaxi Xu
Journal:  Front Immunol       Date:  2021-08-03       Impact factor: 7.561

4.  Chronic schistosome infection leads to modulation of granuloma formation and systemic immune suppression.

Authors:  Steven K Lundy; Nicholas W Lukacs
Journal:  Front Immunol       Date:  2013-02-20       Impact factor: 7.561

5.  Dyarrheal Syndrome in a Patient Co-Infected with Leishmania infantum and Schistosoma mansoni.

Authors:  Gláucia Fernandes Cota; Luciana Inácia Gomes; Bruna Fernandes Pinto; Joanna R Santos-Oliveira; Alda Maria Da-Cruz; Moisés Salgado Pedrosa; Wagner Luiz Tafuri; Ana Rabello
Journal:  Case Rep Med       Date:  2012-11-18

6.  Dendritic cell profile induced by Schistosoma mansoni antigen in cutaneous leishmaniasis patients.

Authors:  Diego Mota Lopes; Jamille Souza Fernandes; Thiago Marconi de Souza Cardoso; Aline Michele Barbosa Bafica; Sérgio Costa Oliveira; Edgar M Carvalho; Maria Ilma Araujo; Luciana Santos Cardoso
Journal:  Biomed Res Int       Date:  2014-09-17       Impact factor: 3.411

7.  Schistosoma mansoni Tegument (Smteg) Induces IL-10 and Modulates Experimental Airway Inflammation.

Authors:  Fábio Vitarelli Marinho; Clarice Carvalho Alves; Sara C de Souza; Cintia M G da Silva; Geovanni D Cassali; Sergio C Oliveira; Lucila G G Pacifico; Cristina T Fonseca
Journal:  PLoS One       Date:  2016-07-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.